secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2022-06-10T23:59:59+00:00
Accession:  0001171843-22-004296
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika shareholders approve 250,000-share increase in 2017 incentive plan, reelect directors
--------------------------------------------------------------------------------

- Stockholders approved amendment increasing shares under 2017 Omnibus Plan from 4.6M to 4.85M; 10.1M in favor, 2.25M against.
- Cheryl R. Blanchard (Ph.D.) reelected as Class II director with 11.36M votes for, 1.11M against; Glenn R. Larsen (Ph.D.) with 11.98M for, 0.32M against.
- Ratification of Deloitte & Touche as auditor passed with 13.13M for, 0.08M against, 15.3K abstain; advisory say-on-pay passed with 12.15M for.
- Meeting turnout: 13.22M shares present (91.07% of voting power).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184322004296/0001171843-22-004296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184322004296/f8k_060822.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-004296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer